TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer.
第一作者:
Rosa A,van Amerongen
第一单位:
Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.
作者:
医学主题词
人类(Humans);男(雄)性(Male);前列腺肿瘤(Prostatic Neoplasms);激肽释放酶类(Kallikreins);受体, 抗原, T细胞(Receptors, Antigen, T-Cell);动物(Animals);细胞系, 肿瘤(Cell Line, Tumor);小鼠(Mice);T淋巴细胞(T-Lymphocytes);抗原, 肿瘤(Antigens, Neoplasm);免疫疗法, 过继(Immunotherapy, Adoptive);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.1158/2326-6066.CIR-24-0119
PMID
40387827
发布时间
2026-09-30
基金项目
LSHM15011/Health Holland
Unrestricted grant/Bellicum Pharmaceuticals
- 浏览0
Cancer immunology research
2025年13卷8期
1145-1159页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



